2022
Pazopanib Is a Potential Treatment for Coronavirus-Induced Lung Injuries.
Luan Y, Yuan Q, Wang Q, Compton S, Wu D, Tang W. Pazopanib Is a Potential Treatment for Coronavirus-Induced Lung Injuries. The Journal Of Immunology 2022, 209: 723-730. PMID: 35914834, PMCID: PMC9378470, DOI: 10.4049/jimmunol.2100968.Peer-Reviewed Original ResearchConceptsLung injuryCOVID-19 patientsPotential treatmentSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Long-term pathological consequencesRespiratory syndrome coronavirus 2Severe acute respiratory syndromeAdministration of pazopanibAmeliorate lung injuryPulmonary disease modelAcute lung injuryEarly disease manifestationsSyndrome coronavirus 2Acute respiratory syndromeCOVID-19Health care systemCoronavirus 2J miceDisease manifestationsTherapeutic effectVirus infectionRespiratory syndromePazopanibInjury
2021
Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3
Yuan Q, Basit A, Liang W, Qu R, Luan Y, Ren C, Li A, Xu X, Liu X, Yang C, Kuo A, Pierce R, Zhang L, Turk B, Hu X, Li F, Cui W, Li R, Huang D, Mo L, Sessa WC, Lee PJ, Kluger Y, Su B, Tang W, He J, Wu D. Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3. Science Translational Medicine 2021, 13 PMID: 33910977, PMCID: PMC8466683, DOI: 10.1126/scitranslmed.abc2499.Peer-Reviewed Original ResearchConceptsAcute lung injuryLung injuryMyeloid cellsLung transplantation recipientsMouse ALI modelPulmonary barrier functionTransplantation recipientsALI modelReactive oxygen species formationPharmacological interventionsPazopanibOxygen species formationVasculature integrityEpithelial cell survivalHigh mortalityMitogen-activated protein kinase kinase kinase 2Barrier functionGenetic inactivationInjuryCell survivalMortalityProtein kinase kinase kinase 2MAP3K3Kinase 2Manifestations